- Home
- OPTN vs ATOS Comparison
OPTN vs ATOS Comparison
Compare OPTN & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- ATOS
- Stock Information
- Founded
- OPTN 2010
- ATOS 2009
- Country
- OPTN United States
- ATOS United States
- Employees
- OPTN N/A
- ATOS N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- OPTN Health Care
- ATOS Health Care
- Exchange
- OPTN Nasdaq
- ATOS Nasdaq
- Market Cap
- OPTN 92.8M
- ATOS 96.8M
- IPO Year
- OPTN 2017
- ATOS 2012
- Fundamental
- Price
- OPTN $9.39
- ATOS $0.82
- Analyst Decision
- OPTN Hold
- ATOS Strong Buy
- Analyst Count
- OPTN 3
- ATOS 3
- Target Price
- OPTN $9.00
- ATOS $7.13
- AVG Volume (30 Days)
- OPTN 32.1K
- ATOS 614.8K
- Earning Date
- OPTN 05-20-2025
- ATOS 05-16-2025
- Dividend Yield
- OPTN N/A
- ATOS N/A
- EPS Growth
- OPTN N/A
- ATOS N/A
- EPS
- OPTN N/A
- ATOS N/A
- Revenue
- OPTN $78,226,000.00
- ATOS N/A
- Revenue This Year
- OPTN $30.49
- ATOS N/A
- Revenue Next Year
- OPTN $13.51
- ATOS N/A
- P/E Ratio
- OPTN N/A
- ATOS N/A
- Revenue Growth
- OPTN 10.20
- ATOS N/A
- 52 Week Low
- OPTN $4.82
- ATOS $0.55
- 52 Week High
- OPTN $20.03
- ATOS $1.74
- Technical
- Relative Strength Index (RSI)
- OPTN 76.14
- ATOS 57.39
- Support Level
- OPTN $9.37
- ATOS $0.78
- Resistance Level
- OPTN $9.45
- ATOS $0.92
- Average True Range (ATR)
- OPTN 0.08
- ATOS 0.07
- MACD
- OPTN -0.07
- ATOS 0.01
- Stochastic Oscillator
- OPTN 80.71
- ATOS 60.93
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.